Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test whether an oral medication (lamivudine) enters the
eye and reduces blood markers of inflammation in people who undergo retinal detachment
surgery (pars plana vitrectomy).
Participants will take the study medication or placebo, and the researchers will measure
blood markers of inflammation before and after surgery. The researchers will also measure the
amount of medication in the blood and fluid inside the participant's eye (which is collected
during surgery).